Diltiazem

• Description:

  Diltiazem is an orally active L-type Ca2+ channel blocker. Diltiazem shows antihypertensive and antiarrhythmic effects. Diltiazem can be used for the research of cardiac arrhythmia, hypertension, and angina pectoris[1][2][3].

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319

• Target:

  Calcium Channel

• Type:

  Reference compound

• Related Pathways:

  Membrane Transporter/Ion Channel; Neuronal Signaling

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Cardiovascular Disease; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/diltiazem.html

• Purity:

  99.70

• Solubility:

  DMSO : 50 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles:

  CN (C) CCN1C2=CC=CC=C2S[C@@H] (C3=CC=C (OC) C=C3) [C@@H] (OC (C) =O) C1=O

• Molecular Formula:

  C22H26N2O4S

• Molecular Weight:

  414.52

• Precautions:

  H302, H315, H319

• References & Citations:

  [1]Yoshinari Niimi, et al. Diltiazem facilitates inactivation of single L-type calcium channels in guinea pig ventricular myocytes. Jpn Heart J. 2003 Nov;44 (6) :1005-14.|[2]S Lin Tang, et l. Structural Basis for Diltiazem Block of a Voltage-Gated Ca2+ Channel. Mol Pharmacol. 2019 Oct; 96 (4) : 485-492.|[3]Anja Mieth , et al. L-type calcium channel inhibitor diltiazem prevents aneurysm formation by blood pressure-independent anti-inflammatory effects. Hypertension. 2013 Dec;62 (6) :1098-104.|[4]S. J. Downing, et al. Diltiazem pharmacokinetics in the rat and relationship between its serum concentration and uterine and cardiovascular effects. Br J Pharmacol. 1987 Aug; 91 (4) : 735-745.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Isoform:

  L-type calcium channel

• Citation 01:

  ACS Environ Au. 2025 Aug 8.|Anal Chem. 2025 Jun 3;97 (21) :11099-11109.|J Cardiovasc Transl Res. 2023 Aug;16 (4) :758-767.|Nat Commun. 2024 Jun 19;15 (1) :5230.|Pharmacol Res Perspect. 2021 Oct;9 (5) :e00879.|medRxiv. 2025 May 21.|Pharmacol Res Perspect. 2020 Apr;8 (2) :e00575.|Vet Sci. 2025 Sep 5;12 (9) :864.|Virology. 2020 Jan 2;539:38-48.

• CAS Number:

  42399-41-7